Treatment with tPA predicts better outcome even if MCA occlusion persists

International Journal of Stroke

Volumn 8, Issue 7, 2013, Pages 496-502

  Kablau, Micha ^a   Alonso, Angelika ^a   Hennerici, Michael G ^a   Fatar, Marc ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Acute stroke therapy; Ischaemic stroke; Reperfusion; rtPA; Thrombolysis; Ultrasound

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DOPPLER ECHOGRAPHY; FEMALE; FIBRINOLYTIC THERAPY; FOLLOW UP; HUMAN; INTERNATIONAL NORMALIZED RATIO; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MIDDLE CEREBRAL ARTERY; MIDDLE CEREBRAL ARTERY OCCLUSION; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; RANKIN SCALE;

ACUTE STROKE THERAPY; ISCHAEMIC STROKE; REPERFUSION; RTPA; THROMBOLYSIS; ULTRASOUND;

AGED; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HUMANS; INFARCTION, MIDDLE CEREBRAL ARTERY; MALE; THROMBOLYTIC THERAPY; TIME; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 84884332715     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1111/j.1747-4949.2011.00750.x     Document Type: Article

References (30)

1. Yasaka M, O'Keefe GJ, Chambers BR etal. Streptokinase in acute stroke: effect on reperfusion and recanalization. Australian streptokinase trial study group. Neurology 1998; 50 : 626-632.
2. Wahlgren N, Ahmed N, Davalos A etal. Thrombolysis with alteplase for acute ischaemic stroke in the safe implementation of thrombolysis in stroke-monitoring study (SITS-MOST): an observational study. Lancet 2007; 369 : 275-282.
3. Delgado MG, Michel P, Naves M etal. Early profiles of clinical evolution after intravenous thrombolysis in an unselected stroke population. J Neurol Neurosurg Psychiatry 2010; 81 : 282-285.
4. Singer OC, Berkefeld J, Lorenz MW etal. Risk of symptomatic intracerebral hemorrhage in patients treated with intra-arterial thrombolysis. Cerebrovasc Dis 2009; 27 : 368-374.
5. Lansberg MG, Albers GW, Wijman CA. Symptomatic intracerebral hemorrhage following thrombolytic therapy for acute ischemic stroke: a review of the risk factors. Cerebrovasc Dis 2007; 24 : 1-10.
6. Hacke W, Kaste M, Fieschi C etal. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian acute stroke study investigators. Lancet 1998; 352 : 1245-1251.
7. Kane I, Sandercock P, Wardlaw J. Magnetic resonance perfusion diffusion mismatch and thrombolysis in acute ischaemic stroke: a systematic review of the evidence to date. J Neurol Neurosurg Psychiatry 2007; 78 : 485-491.
8. Gerriets T, Goertler M, Stolz E etal. Feasibility and validity of transcranial duplex sonography in patients with acute stroke. J Neurol Neurosurg Psychiatry 2002; 73 : 17-20.
9. Malferrari G, Bertolino C, Casoni F etal. The eligible study: ultrasound assessment in acute ischemic stroke within 3 hours. Cerebrovasc Dis 2007; 24 : 469-476.
10. Miteff F, Levi CR, Bateman GA, Spratt N, McElduff P, Parsons MW. The independent predictive utility of computed tomography angiographic collateral status in acute ischaemic stroke. Brain 2009; 132 : 2231-2238.
11. The National Institute of Neurological Disorders and Stroke rt-PA stroke study group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333 : 1581-1587.
12. Ovbiagele B, Saver JL. Day-90 acute ischemic stroke outcomes can be derived from early functional activity level. Cerebrovasc Dis 2010; 29 : 50-56.
13. Meiner Z, Sajin A, Schwartz I etal. Rehabilitation outcomes of stroke patients treated with tissue plasminogen activator. PM R 2010; 2 : 698-702.
14. Lees KR, Bluhmki E, von Kummer R etal. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010; 375 : 1695-1703.
15. Albers GW, Clark WM, Madden KP, Hamilton SA. Atlantis trial: results for patients treated within 3 hours of stroke onset. Alteplase thrombolysis for acute noninterventional therapy in ischemic stroke. Stroke 2002; 33 : 493-495.
16. Hacke W, Kaste M, Bluhmki E etal. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008; 359 : 1317-1329.
17. Hofmeijer J, Kappelle LJ, Algra A, Amelink GJ, van Gijn J, van der Worp HB. Surgical decompression for space-occupying cerebral infarction (the hemicraniectomy after middle cerebral artery infarction with life-threatening edema trial (HAMLET)): a multicentre, open, randomised trial. Lancet Neurol 2009; 8 : 326-333.
18. Albers GW, Thijs VN, Wechsler L etal. Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Ann Neurol 2006; 60 : 508-517.
19. Davis SM, Donnan GA, Parsons MW etal. Effects of alteplase beyond 3h after stroke in the echoplanar imaging thrombolytic evaluation trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol 2008; 7 : 299-309.
20. Yang DY, Pan HC, Chen CJ, Cheng FC, Wang YC. Effects of tissue plasminogen activator on cerebral microvessels of rats during focal cerebral ischemia and reperfusion. Neurol Res 2007; 29 : 274-282.
21. Cheng B, Golsari A, Fiehler J, Rosenkranz M, Gerloff C, Thomalla G. Dynamics of regional distribution of ischemic lesions in middle cerebral artery trunk occlusion relates to collateral circulation. J Cereb Blood Flow Metab 2011; 31 : 36-40.
22. Kleinschnitz C, Stoll G, Bendszus M etal. Targeting coagulation factor xii provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J Exp Med 2006; 203 : 513-518.
23. Nedelmann M, Ritschel N, Doenges S etal. Combined contrast-enhanced ultrasound and rt-PA treatment is safe and improves impaired microcirculation after reperfusion of middle cerebral artery occlusion. J Cereb Blood Flow Metab 2010; 30 : 1712-1720.
24. Indyk JA, Chen ZL, Tsirka SE, Strickland S. Laminin chain expression suggests that laminin-10 is a major isoform in the mouse hippocampus and is degraded by the tissue plasminogen activator/plasmin protease cascade during excitotoxic injury. Neuroscience 2003; 116 : 359-371.
25. Nicole O, Docagne F, Ali C etal. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med 2001; 7 : 59-64.
26. Lopez-Atalaya JP, Roussel BD, Levrat D etal. Toward safer thrombolytic agents in stroke: molecular requirements for NMDA receptor-mediated neurotoxicity. J Cereb Blood Flow Metab 2008; 28 : 1212-1221.
27. Michaluk P, Mikasova L, Groc L, Frischknecht R, Choquet D, Kaczmarek L. Matrix metalloproteinase-9 controls NMDA receptor surface diffusion through integrin beta1 signaling. J Neurosci 2009; 29 : 6007-6012.
28. Rosell A, Cuadrado E, Ortega-Aznar A, Hernandez-Guillamon M, Lo EH, Montaner J. Mmp-9-positive neutrophil infiltration is associated to blood-brain barrier breakdown and basal lamina type IV collagen degradation during hemorrhagic transformation after human ischemic stroke. Stroke 2008; 39 : 1121-1126.
29. Cipolla MJ, Lessov N, Clark WM, Haley EC Jr. Postischemic attenuation of cerebral artery reactivity is increased in the presence of tissue plasminogen activator. Stroke 2000; 31 : 940-945.
30. Larrue V, von Kummer RR, Muller A, Bluhmki E. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian acute stroke study (ECASS II). Stroke 2001; 32 : 438-441.